438 Identification of Gene Expression Signature to Predict Anti-tumor Efficacy of MET/VEGFR Inhibitor, TAS-115

significance was lost when jointly modelling biomarkers. Pts having IL8 levels <80 pg/ml had greater response (approaching 80%) and 6-month OS (60%) probability than those with a level 80, for whom a dramatic fall was observed. Conclusions: Both IL8 and TGF-b had a prognostic value while IL8 modulation was also associated with response probability. If confirmed in a larger series, these markers may serve to select pts most likely to get a benefit from PZP. There is a rationale for a sequence/combination with PZP and a phase 2 study of an anti-TGF-b receptor ALK1moAb (PF-03446962) for refractory UC is currently recruiting (ClinicalTrials.gov NCT01620970).